Similar Items: Pharmacoeconomic Analysis of Osimertinib Compared to Earlier‐Generation EGFR Inhibitors in EGFR‐Mutated NSCLC: A Systematic Review
- Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management
- Dynamic therapeutic response to osimertinib and immunotherapy in an EGFR L747S and L858R co-mutant NSCLC
- MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib‐Resistant MET‐Amplified, EGFR‐Mutated Non‐Small Cell Lung Cancer
- EGFR Mutations and Recurrence Outcomes in Resected Non‐Small Cell Lung Cancer: An Updated 2015–2025 Systematic Review and Meta‐Analysis
- Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report
- Interleukin‐1α‐Mediated Activation of TNF‐α/NF‐κB Signaling Confers Resistance to Osimertinib in EGFR‐Mutant Non‐Small‐Cell Lung Cancer